Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLSTER
2023-503740-14-00Phase 2Completed
- Sponsor
- Lisata Therapeutics
- Start
- Aug 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of certepetide in cholangiocarcinoma (CCA), gallbladder cancer and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Lisata Therapeutics. Primary endpoint: Incidence and severity of adverse events. Started Aug 2023; status: completed.
02
Drugs
certepetide
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-503740-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503740-14-00.